Migraine

CNS 8 original drugs

Novel Drugs

Reformulations

Drug Targets

CNS indication. Migraine has 8 FDA-approved novel treatments, led by Pfizer, with 87 active industry clinical trials across 22 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Migraine Market Leaders

Companies with the most FDA-approved novel Migraine drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

Eptinezumab

H. Lundbeck A/S

Estimated · fresh NCT04965675

Q4 2026

Rimegepant

Pfizer

Estimated · fresh NCT06616194

Q4 2026

Rimegepant

Pfizer

Estimated · fresh NCT06641466

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Migraine Treatments by Mechanism

Top 8 mechanisms across 40 industry trials with a known mechanism of action.

See full pipeline →

Calcitonin Gene-related Peptide Receptor Antagonist

22 trials 7 active 2 sponsors

Acetylcholine Release Inhibitor

6 trials 2 active 2 sponsors

Cytochrome P450 3A4 Inducers [MoA]

2 trials 1 active 2 sponsors

Serotonin-1b and Serotonin-1d Receptor Agonist

5 trials 4 sponsors

5-HT 1B/5-HT 1D

2 trials 1 sponsor

5-HT1B/5-HT1D/COX-1/COX-2

1 trials 1 sponsor

Nonsteroidal Anti-inflammatory Drug

1 trials 1 sponsor

5-HT1B/5-HT1D

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Migraine Clinical Pipeline by Phase

309 industry-sponsored trials across 79 sponsors

View full landscape →

Showing 40 of 40 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Upsher-Smith Laboratories	Qudexy XR	Cytochrome P450 3A4 Inducers [MoA]	RECRUITING	2026-09	NCT04748601
Pfizer	Rimegepant	—	RECRUITING	2028-05-15	NCT07609914
Alasht Pharmed	—	—	RECRUITING	2025-09-16	NCT07093138
H. Lundbeck A/S	Eptinezumab	—	ACTIVE NOT RECRUITING	2026-06-05	NCT06701526
Theranica	—	—	ACTIVE NOT RECRUITING	2026-01-20	NCT07336056
Theranica	—	—	COMPLETED	2026-01-25	NCT07336420
Theranica	—	—	COMPLETED	2025-06-10	NCT06976723
Pfizer	Rimegepant	—	COMPLETED	2025-03-31	NCT05518123
Pfizer	Rimegepant	—	COMPLETED	2025-03-10	NCT05509400
H. Lundbeck A/S	Eptinezumab	—	COMPLETED	2024-10-22	NCT05452239
Pfizer	Rimegepant 75mg daily dosing	—	COMPLETED	2024-10-22	NCT05217927
Pfizer	Rimegepant	—	COMPLETED	2024-07-02	NCT05207865
Amgen	Erenumab	—	COMPLETED	2023-10-26	NCT04252742
Amgen	Erenumab	—	COMPLETED	2023-09-28	NCT04825678
Eli Lilly	Galcanezumab	—	COMPLETED	2023-05-23	NCT05127486
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2023-04-04	NCT05264129
Novartis	Erenumab	—	COMPLETED	2023-02-23	NCT04084314
Amgen	Erenumab	—	COMPLETED	2023-01-18	NCT04265755
Amgen	Erenumab 70 mg	—	COMPLETED	2022-12-01	NCT03971071
Teva Branded Pharmaceutical Products R&D, Inc.	Fremanezumab	—	COMPLETED	2022-08-31	NCT04041284
David True	Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]	—	COMPLETED	2022-01-10	NCT04461795
Amgen	AMG334	—	COMPLETED	2021-10-01	NCT03927144
Novartis	erenumab	—	COMPLETED	2021-07-05	NCT03977649
Eli Lilly	Galcanezumab	—	COMPLETED	2021-03-05	NCT04294147
Novartis	Erenumab	—	COMPLETED	2020-07-29	NCT03828539
AbbVie	onabotulinumtoxinA	Acetylcholine Release Inhibitor [EPC]	COMPLETED	2017-05-09	NCT02191579
Depomed	Diclofenac Potassium for Oral Solution	—	COMPLETED	2016-02	NCT02287376
AbbVie	onabotulinumtoxinA	Acetylcholine Release Inhibitor [EPC]	COMPLETED	2015-11	NCT01516892
Jiangsu Kanion Pharmaceutical Co., Ltd	Tianshu capsule	—	COMPLETED	2015-04	NCT02035111
AbbVie	botulinum toxin Type A	—	COMPLETED	2015-02	NCT02147561
AbbVie	OnabotulinumtoxinA	Acetylcholine Release Inhibitor [EPC]	COMPLETED	2014-09	NCT01833130
Tian Medical Inc.	Marcaine	—	COMPLETED	2014-02	NCT01709708
AstraZeneca	Zolmitriptan	Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]	COMPLETED	2013-10	NCT01211145
Novartis	Aspirin, acetaminophen and caffeine	—	COMPLETED	2011-03	NCT01248468
Zogenix, Inc.	Sumatriptan	Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]	COMPLETED	2010-04-30	NCT01016834
GSK	sumatriptan and naproxen sodium combination tablet	—	COMPLETED	2009-11	NCT00792636
Supernus Pharmaceuticals, Inc.	SPN-538	—	TERMINATED	2023-03-01	NCT04050293
H. Lundbeck A/S	Eptinezumab	—	TERMINATED	2023-02-17	NCT05284019
Amgen	Erenumab	—	TERMINATED	2021-07-28	NCT03912337
Vincent Martin, MD	Theramine (medical food/old drug)	—	TERMINATED	2014-12	NCT01944059

Showing 100 of 149 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
H. Lundbeck A/S	Eptinezumab	—	RECRUITING	2026-09-05	NCT04965675
Pfizer	Rimegepant	—	RECRUITING	2026-10-08	NCT06616194
Pfizer	Rimegepant	—	RECRUITING	2026-11-29	NCT06641466
Merz Therapeutics GmbH	Xeomin	Acetylcholine Release Inhibitor [EPC]	RECRUITING	2027-03	NCT07018700
AbbVie	Ubrogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	RECRUITING	2027-05	NCT05125302
AbbVie	Ubrogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	RECRUITING	2027-06	NCT06417775
H. Lundbeck A/S	Eptinezumab	—	RECRUITING	2027-07-06	NCT05897320
Merz Therapeutics GmbH	Xeomin	Acetylcholine Release Inhibitor [EPC]	RECRUITING	2027-10	NCT07018713
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	RECRUITING	2028-03	NCT05711394
H. Lundbeck A/S	Eptinezumab	—	RECRUITING	2028-04-30	NCT05164172
Pfizer	Rimegepant/BHV3000	—	RECRUITING	2029-01-09	NCT04649242
Pfizer	Rimegepant (PF-07899801)	—	RECRUITING	2030-07-31	NCT04743141
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	RECRUITING	2031-03	NCT06810505
Pfizer	Rimegepant	—	RECRUITING	2031-11-29	NCT05156398
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	ACTIVE NOT RECRUITING	2027-02	NCT06806293
Ipsen	Botulinum toxin type A	—	ACTIVE NOT RECRUITING	2026-05-27	NCT06047457
Ipsen	Botulinum toxin type A	—	ACTIVE NOT RECRUITING	2026-05-21	NCT06047444
Eli Lilly	Galcanezumab	—	ACTIVE NOT RECRUITING	2025-12-10	NCT04616326
Amgen	Erenumab Dose 1	—	ACTIVE NOT RECRUITING	2025-11-19	NCT03836040
Eli Lilly	Galcanezumab	—	ACTIVE NOT RECRUITING	2025-11-14	NCT03432286
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	ACTIVE NOT RECRUITING	2025-07-07	NCT06241313
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	ACTIVE NOT RECRUITING	2025-04-28	NCT05748483
Kallyope Inc.	Elismetrep	—	NOT YET RECRUITING	2027-02	NCT07645924
IntraBio Inc	N-Acetyl-L-Leucine	—	NOT YET RECRUITING	2027-08-01	NCT07221292
Dr George Medvedev	Eptinezumab	—	NOT YET RECRUITING	2025-12-30	NCT06428838
AbbVie	Atogepant 60 mg	—	COMPLETED	2025-10-20	NCT04686136
Pfizer	Rimegepant	—	COMPLETED	2025-08-25	NCT05810038
Teva Branded Pharmaceutical Products R&D LLC	Fremanezumab	—	COMPLETED	2025-08-15	NCT04530110
Pfizer	Zavegepant	—	COMPLETED	2025-05-30	NCT05989048
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2025-05-02	NCT05216263
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2025-03-01	NCT05861427
Amgen	Erenumab Dose 1	—	COMPLETED	2025-01-08	NCT03832998
Teva Branded Pharmaceutical Products R&D, Inc.	Fremanezumab	—	COMPLETED	2024-11-29	NCT04464707
Axsome Therapeutics, Inc.	AXS-07 (meloxicam-rizatriptan)	—	COMPLETED	2024-11-27	NCT05550207
Eurofarma Laboratorios S.A.	Rizatriptan 10 mg + Naproxen 550mg	—	COMPLETED	2024-10-30	NCT04384367
H. Lundbeck A/S	Eptinezumab	—	COMPLETED	2024-10-01	NCT04921384
AbbVie	Atogepant 60 mg	—	COMPLETED	2024-06-11	NCT04437433
H. Lundbeck A/S	Eptinezumab	—	COMPLETED	2024-06-08	NCT05064371
Click Therapeutics, Inc.	—	—	COMPLETED	2024-05-21	NCT06004388
Teva Branded Pharmaceutical Products R&D, Inc.	Fremanezumab	—	COMPLETED	2024-03-13	NCT04458857
Pfizer	Rimegepant 75mg Orally Disintegrating Tablets (ODT)	—	COMPLETED	2024-02-06	NCT05371652
Teva Branded Pharmaceutical Products R&D, Inc.	Fremanezumab	—	COMPLETED	2024-01-31	NCT05458011
Pfizer	Rimegepant 25 MG	—	COMPLETED	2024-01-19	NCT05399459
Pfizer	Rimegepant	—	COMPLETED	2024-01-18	NCT05399485
Tian Medical Inc.	—	—	COMPLETED	2023-11-15	NCT03337620
RDC Clinical Pty Ltd	Palmitoylethanolamide sold as Levagen +	—	COMPLETED	2023-03-09	NCT05046522
Satsuma Pharmaceuticals, Inc.	Dihydroergotamine	—	COMPLETED	2023-01-16	NCT04406649
Satsuma Pharmaceuticals, Inc.	Dihydroergotamine	—	COMPLETED	2022-10-13	NCT04940390
AbbVie	Atogepant 60 mg	—	COMPLETED	2022-08-04	NCT04740827
H. Lundbeck A/S	Eptinezumab	—	COMPLETED	2022-05-23	NCT04772742
AbbVie	Ubrogepant 100 mg	—	COMPLETED	2022-04-19	NCT04492020
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2022-01-20	NCT04829747
AbbVie	Atogepant 30 mg	—	COMPLETED	2022-01-20	NCT03855137
Pfizer	Zavegepant (BHV-3500)	—	COMPLETED	2021-12-09	NCT04408794
Pfizer	Rimegepant	—	COMPLETED	2021-11-24	NCT04574362
Pfizer	Zavegepant	—	COMPLETED	2021-10-10	NCT04571060
Novartis	Erenumab	—	COMPLETED	2021-08-11	NCT03867201
Eli Lilly	Galcanezumab	—	COMPLETED	2021-07-27	NCT03963232
H. Lundbeck A/S	Eptinezumab	—	COMPLETED	2021-07-15	NCT04418765
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2021-03-31	NCT03939312
Otsuka Pharmaceutical Co., Ltd.	Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.	—	COMPLETED	2020-11-11	NCT04355117
IlDong Pharmaceutical Co Ltd	Lasmiditan 50mg	—	COMPLETED	2020-10-30	NCT04218162
Axsome Therapeutics, Inc.	AXS-07	—	COMPLETED	2020-09-22	NCT04068051
Satsuma Pharmaceuticals, Inc.	Dihydroergotamine	—	COMPLETED	2020-07-31	NCT03901482
H. Lundbeck A/S	Eptinezumab	—	COMPLETED	2020-07-08	NCT04152083
Impax Laboratories, LLC	ZNS	—	COMPLETED	2020-07-02	NCT03275922
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2020-06-19	NCT03777059
Otsuka Pharmaceutical Co., Ltd.	TEV-48125	—	COMPLETED	2020-06-16	NCT03303105
Eli Lilly	Lasmiditan	—	COMPLETED	2020-06-12	NCT03670810
AbbVie	Standard of Care (SOC) Migraine Preventive Medication	—	COMPLETED	2020-05-21	NCT03700320
Impel Pharmaceuticals	—	—	COMPLETED	2020-03-17	NCT03557333
Axsome Therapeutics, Inc.	AXS-07 (MoSEIC meloxicam and rizatriptan)	—	COMPLETED	2020-03-16	NCT04163185
Amgen	Erenumab	—	COMPLETED	2020-03-16	NCT03812224
Novartis	Erenumab	—	COMPLETED	2020-01-13	NCT03333109
Pfizer	Rimegepant	—	COMPLETED	2019-12-10	NCT03732638
Axsome Therapeutics, Inc.	AXS-07 (MoSEIC meloxicam and rizatriptan)	—	COMPLETED	2019-12-10	NCT03896009
Otsuka Pharmaceutical Co., Ltd.	TEV-48125	—	COMPLETED	2019-11-30	NCT03303079
Otsuka Pharmaceutical Co., Ltd.	TEV-48125	—	COMPLETED	2019-11-22	NCT03303092
Pfizer	Zavegepant	—	COMPLETED	2019-10-31	NCT03872453
Eli Lilly	Lasmiditan	—	COMPLETED	2019-08-20	NCT02565186
Eli Lilly	Galcanezumab	—	COMPLETED	2019-08-10	NCT02959190
Pfizer	Rimegepant	—	COMPLETED	2019-07-15	NCT03266588
Eli Lilly	Galcanezumab	—	COMPLETED	2019-06-19	NCT03559257
Zosano Pharma Corporation	M207 Microneedle System	—	COMPLETED	2019-05-17	NCT03282227
Pfizer	Rimegepant	—	COMPLETED	2018-10-08	NCT03461757
Teva Branded Pharmaceutical Products R&D, Inc.	Fremanezumab	—	COMPLETED	2018-10-02	NCT03308968
AbbVie	Ubrogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2018-08-02	NCT02873221
Teva Branded Pharmaceutical Products R&D, Inc.	Fremanezumab	—	COMPLETED	2018-06-06	NCT02638103
Allodynic Therapeutics, Inc	Naltrexone and Acetaminophen Combination	—	COMPLETED	2018-05-07	NCT03185143
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2018-04-02	NCT02848326
Alder Biopharmaceuticals, Inc.	ALD403 (Eptinezumab)	—	COMPLETED	2018-04	NCT02985398
Pfizer	Rimegepant	—	COMPLETED	2018-01-25	NCT03237845
AbbVie	Ubrogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2018-01-25	NCT02867709
Pfizer	Rimegepant	—	COMPLETED	2018-01-21	NCT03235479
Novartis	AMG334 (70 mg) Pre-Filled Syringe (PFS)	—	COMPLETED	2018-01-18	NCT03096834
AbbVie	Ubrogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2017-12-13	NCT02828020
BioDelivery Sciences International	DFN-15 Active	—	COMPLETED	2017-11	NCT03009019
BioDelivery Sciences International	DFN-15 Active	—	COMPLETED	2017-11	NCT03006276
Alder Biopharmaceuticals, Inc.	ALD403 (Eptinezumab)	—	COMPLETED	2017-11	NCT02974153
Eli Lilly	Lasmiditan 50 mg	—	COMPLETED	2017-06-30	NCT02605174

Showing 63 of 63 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Sichuan Purity Pharmaceutical Technology Co., Ltd.	PRT-064040 nasal spray	—	RECRUITING	2026-09	NCT07304518
Aspeya, Inc.	—	—	RECRUITING	2026-12	NCT07646613
AbbVie	MEDI0618	—	RECRUITING	2026-12-18	NCT06602479
Ipsen	IPN10200	—	RECRUITING	2027-01-31	NCT06625060
Evommune, Inc.	EVO756, Dose 1	—	NOT YET RECRUITING	2027-10	NCT07616128
H. Lundbeck A/S	Lu AG09222	—	COMPLETED	2026-01-16	NCT06323928
Kallyope Inc.	Elismetrep (K-304) Dose Level 1	—	COMPLETED	2025-08-11	NCT06848075
Manistee Therapeutics	MTX101	—	COMPLETED	2025-06-27	NCT06728553
Biohaven Therapeutics Ltd.	BHV-2100	—	COMPLETED	2025-03-24	NCT06603623
AEON Biopharma, Inc.	ABP-450	—	COMPLETED	2024-06-19	NCT04845178
Tonix Pharmaceuticals, Inc.	TNX-1900	—	COMPLETED	2023-10-08	NCT05679908
H. Lundbeck A/S	Lu AG09222	—	COMPLETED	2023-01-19	NCT05133323
Eli Lilly	LY3451838	—	COMPLETED	2022-11-09	NCT04498910
Cerecin	Tricaprilin	—	COMPLETED	2022-02-07	NCT04437199
Asarina Pharma	Sepranolone injection low dose	—	COMPLETED	2021-05-15	NCT04102995
Eli Lilly	Lasmiditan	—	COMPLETED	2020-06-08	NCT03962738
Lateral Pharma Pty Ltd	LAT8881	—	COMPLETED	2020-02-15	NCT04153409
Charleston Laboratories, Inc	Arm 1: CL-H1T	—	COMPLETED	2019-08-27	NCT03877718
AOBiome LLC	B244	—	COMPLETED	2019-06-17	NCT03488563
Eli Lilly	Galcanezumab	—	COMPLETED	2019-01-18	NCT02959177
Amgen	AMG 301	—	COMPLETED	2018-10-16	NCT03238781
Allodynic Therapeutics, Inc	Low-Dose Naltrexone and Acetaminophen Combination	—	COMPLETED	2018-07-26	NCT03194555
Allodynic Therapeutics, Inc	Naltrexone and Acetaminophen	—	COMPLETED	2018-02-08	NCT06245902
Allodynic Therapeutics, Inc	Naltrexone and Acetaminophen	—	COMPLETED	2018-02-08	NCT03061734
Amgen	Erenumab	—	COMPLETED	2017-09-25	NCT02630459
Amgen	Erenumab	—	COMPLETED	2017-05-26	NCT02174861
Upsher-Smith Laboratories	Sumatriptan 10 mg Nasal Spray	—	COMPLETED	2017-02-10	NCT02856802
Dr. Reddy's Laboratories Limited	DFN-11	—	COMPLETED	2016-04	NCT02571049
Alder Biopharmaceuticals, Inc.	ALD403	—	COMPLETED	2016-03	NCT02275117
Amgen	Erenumab	—	COMPLETED	2016-02-24	NCT02066415
Dr. Reddy's Laboratories Limited	DFN-15 Dose A (treatment A)	—	COMPLETED	2015-12-01	NCT02472418
Trigemina, Inc	TI-001	—	COMPLETED	2015-10	NCT01839149
Eli Lilly	Galcanezumab	—	COMPLETED	2015-08-19	NCT02163993
Teva Branded Pharmaceutical Products R&D, Inc.	LBR-101 High Dose	—	COMPLETED	2015-02-28	NCT02021773
Teva Branded Pharmaceutical Products R&D, Inc.	LBR-101 High Dose	—	COMPLETED	2015-01-31	NCT02025556
Achelios Therapeutics	ELS-M11	—	COMPLETED	2014-11	NCT02057315
Amgen	Erenumab	—	COMPLETED	2014-09-25	NCT01952574
Eli Lilly	LY2951742	—	COMPLETED	2013-07	NCT01625988
AbbVie	MK-1602	—	COMPLETED	2012-12-01	NCT01613248
AbbVie	MK-1602	—	COMPLETED	2012-11	NCT01657370
Merck	MK-6096	—	COMPLETED	2012-10-03	NCT01513291
Pfizer	Rimegepant	—	COMPLETED	2012-05	NCT01430442
Duramed Research	91-day Levonorgestrel Oral Contraceptive	—	COMPLETED	2011-08	NCT00781456
Novartis	BGG492	—	COMPLETED	2010-08	NCT00892203
XenoPort, Inc.	GSK1838262	—	COMPLETED	2010-06	NCT00742209
Bial - Portela C S.A.	ESL 1200 mg	—	COMPLETED	2010-06	NCT01820559
NeurAxon Inc.	NXN-188	—	COMPLETED	2010-03	NCT00920686
Eli Lilly	Lasmiditan	—	COMPLETED	2010-02	NCT00883051
NeurAxon Inc.	NXN-188	—	COMPLETED	2010-02	NCT00959751
Merck	ibuprofen	Nonsteroidal Anti-inflammatory Drug [EPC]	COMPLETED	2009-08-24	NCT00758836
Capnia, Inc.	Nasal CO2	—	COMPLETED	2009-06	NCT00690716
Boehringer Ingelheim	BI 44370 TA Low Dose	—	COMPLETED	2009-05	NCT00751803
Merck	MK3207- 2.5 mg	—	COMPLETED	2009-01	NCT00712725
Kallyope Inc.	K-645 dose level 1	—	TERMINATED	2025-11-07	NCT07116499
AEON Biopharma, Inc.	ABP-450	—	TERMINATED	2024-07-31	NCT05016661
Capnia, Inc.	Nasal Carbon Dioxide	—	TERMINATED	2013-04	NCT01253915
Eli Lilly	LY2300559	—	TERMINATED	2012-04	NCT01184508
Addex Pharma S.A.	ADX10059	—	TERMINATED	2010-01	NCT00820105
Merck	Telcagepant 140 mg	—	TERMINATED	2009-05-20	NCT00797667
Eli Lilly	LY2590443	—	TERMINATED	2009-05	NCT00804973
Allodynic Therapeutics, Inc	Stage 1: Naltrexone/Acetaminophen	—	WITHDRAWN	2025-12-02	NCT05685225
Novartis	BGG492	—	WITHDRAWN	2016-11	NCT01617941
D-Pharm Ltd.	DP-VPA	—	WITHDRAWN	2009-06	NCT00640965

Showing 57 of 57 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Pfizer	ODT2 Test formulation	—	RECRUITING	2026-08-31	NCT07594769
Pfizer	Zavegepant	—	RECRUITING	2027-08-12	NCT06995729
Sichuan Purity Pharmaceutical Technology Co., Ltd.	PRT-064040 nasal spray	—	COMPLETED	2025-09-08	NCT07016516
H. Lundbeck A/S	Ubrogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2025-07-11	NCT06578585
Vaxxinity, Inc.	UB-313	—	COMPLETED	2023-10-06	NCT05477095
Humanis Saglık Anonim Sirketi	Ibuprofen/ Paracetamol tablets	—	COMPLETED	2023-09-14	NCT06180070
H. Lundbeck A/S	Lu AG09222	—	COMPLETED	2022-10-30	NCT05304910
H. Lundbeck A/S	Eptinezumab	—	COMPLETED	2022-10-20	NCT04537429
Amgen	AMG 334 Dose 1	—	COMPLETED	2021-11-23	NCT03499119
Zosano Pharma Corporation	Treatment A: M207 3.8 mg "MiniMac"	—	COMPLETED	2021-09-02	NCT04969497
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2021-06-18	NCT04818515
Satsuma Pharmaceuticals, Inc.	Dihydroergotamine	—	COMPLETED	2021-06-04	NCT05337254
SK Chemicals Co., Ltd.	Topiramate	Cytochrome P450 3A4 Inducers [MoA]	COMPLETED	2020-10-06	NCT04401137
H. Lundbeck A/S	ALD1910	—	COMPLETED	2020-08-19	NCT04197349
Eli Lilly	Lasmiditan	—	COMPLETED	2020-01-19	NCT03988088
AbbVie	Ubrogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2019-12-23	NCT04179474
Zosano Pharma Corporation	M207 3.8 mg "Sled" (two 1.9 mg patches made on a "Sled" coater, foil pouches)	—	COMPLETED	2019-06-28	NCT03978403
Zosano Pharma Corporation	A: M207 3.8mg, 30 min, upper arm	—	COMPLETED	2018-11-20	NCT03708744
Satsuma Pharmaceuticals, Inc.	Dihydroergotamine	—	COMPLETED	2018-11-07	NCT03874832
Sorrento Therapeutics, Inc.	Sumatriptan Succinate Oral Tablet	—	COMPLETED	2018-03-28	NCT03229798
Eli Lilly	Lasmiditan	—	COMPLETED	2018-01-15	NCT03247790
Impel Pharmaceuticals	Dihydroergotamine Mesylate (DHE)	—	COMPLETED	2017-12-01	NCT03401346
Amgen	Erenumab	—	COMPLETED	2017-09-28	NCT02542605
Dr. Reddy's Laboratories Limited	DFN-15 (fasted)	—	COMPLETED	2017-08-22	NCT03282838
Eli Lilly	lasmiditan 200 mg	—	COMPLETED	2017-07-17	NCT03040479
Eli Lilly	Lasmiditan	—	COMPLETED	2017-06-08	NCT03012334
Eli Lilly	Lasmiditan	—	COMPLETED	2017-06-02	NCT03009162
Eli Lilly	lasmiditan 200 mg	—	COMPLETED	2017-04-13	NCT03076970
Acorda Therapeutics	CVT-427 (zolmitriptan inhalation powder)	—	COMPLETED	2016-12	NCT02905227
Amgen	Erenumab	—	COMPLETED	2016-09-09	NCT02792517
Acorda Therapeutics	zolmitriptan	Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]	COMPLETED	2015-12	NCT02609945
Cefaly Technology	—	—	COMPLETED	2015-10	NCT02411513
Eli Lilly	LY2951742	—	COMPLETED	2015-01	NCT02104765
NuPathe Inc.	PROT-CL-NP101-015.01	—	COMPLETED	2014-11	NCT02684409
Amgen	AMG 333	—	COMPLETED	2014-09	NCT01953341
Amgen	Erenumab	—	COMPLETED	2014-07-10	NCT01723514
Alder Biopharmaceuticals, Inc.	ALD403	—	COMPLETED	2013-12	NCT01772524
Amgen	Erenumab	—	COMPLETED	2013-03-27	NCT01688739
Pfizer	PF-04427429	—	COMPLETED	2013-01	NCT01511497
Alder Biopharmaceuticals, Inc.	ALD403	—	COMPLETED	2012-12	NCT01579383
Pfizer	BMS-927711 (CGRP Antagonist)	—	COMPLETED	2012-09	NCT01445067
Eli Lilly	LY2951742	—	COMPLETED	2012-04	NCT01337596
Optinose US Inc.	Sumatriptan	Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]	COMPLETED	2012-02	NCT01507610
Merck	telcagepant	—	COMPLETED	2011-07-26	NCT01315847
AstraZeneca	Rapimelt	—	COMPLETED	2010-10	NCT01085123
GSK	This is a pharmacokinetic study (Treximet)	—	COMPLETED	2009-09-10	NCT00989625
NuPathe Inc.	Sumatriptan succinate	5-HT1B/5-HT1D	COMPLETED	2009-09	NCT00723983
Boehringer Ingelheim	BI 44370 TA tablet	—	COMPLETED	2009-03	NCT00743015
NuPathe Inc.	NP101 Sumatriptan Iontophoretic Transdermal Patch	—	COMPLETED	2008-07	NCT00720018
GSK	TREXIMA™	—	COMPLETED	2008-06-14	NCT00875784
Merck	MK0974 Ethanolate formulation	—	COMPLETED	2008-05	NCT00965887
Merck	MK0974 tablet	—	COMPLETED	2008-05	NCT00966030
Trevena Inc.	Part A: TRV250-20mg/ml	—	TERMINATED	2020-02-17	NCT04201080
Amgen	AMG 333	—	TERMINATED	2014-10	NCT02132429
Pfizer	PF-05180999	—	TERMINATED	2014-04	NCT01981499
Ethicon, Inc.	—	—	TERMINATED	2013-07	NCT01855672
Pfizer	PF-05180999 Tablets	—	WITHDRAWN	2015-01	NCT01981486

Novel Migraine Drugs by Company (New molecular entities)

6 companies have an FDA-approved novel drug for Migraine.

Pfizer 2 drugs

ZAVZPRET

ZAVEGEPANT HYDROCHLORIDE

Eli Lilly 2 drugs

Teva 1 drug

AbbVie 1 drug

Amgen 1 drug

Lundbeck Seattle BioPharmaceuticals, Inc. 1 drug

VYEPTI

EPTINEZUMAB-JJMR

BLA 2020

Reformulations (21 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.